Chaperone Clinical Study for Children with Nearsightedness (IL)
If your child has myopia (nearsightedness) he/she may qualify for the CHAPERONE Clinical Study, now being offered at select centers throughout the U.S.
Summary of Study
If your child has myopia (nearsightedness) he/she may qualify for the CHAPERONE Clinical Study, now being offered at select centers throughout the U.S. The study is testing 2 different strengths of microdosed atropine eye solution for slowing the
progression of myopia in children.
Initial eligibility criteria:
- Aged 3 years - 12 years, with a diagnosis of myopia (nearsightedness)
- Glasses or contact lens prescription of -1.00 to -6.00 diopters
- Able and willing to use medication administered as a spray mist to each eye once daily before bedtime for a period of 4 years
- No previous use of other myopia drug therapies (atropine, pirenzepene, or other topical anti-muscarinic drug)
Potential benefits:
- Study-related care free of charge
- Compensation for time and travel
Caution: New Drug - Limited by Federal (United States) Law to Investigational Use
Contact Information
Please contact Katarina at 630-743-4844.